C6461006: AN INTERVENTIONAL PHASE 1b/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY ANTITUMOR ACTIVITY AND PHARMACOKINETICS OF PF08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
